<DOC>
	<DOCNO>NCT02238756</DOCNO>
	<brief_summary>The purpose clinical trial investigate safety tolerability IM administer CV8102 IM administer combination CV8102 rabies vaccine human .</brief_summary>
	<brief_title>Safety Tolerability CV8102 Alone Combination With Rabies Virus Vaccine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<criteria>1 . Compliant protocol procedure available clinical F/U protocoldefined end trial 2 . Physical examination laboratory result without clinically significant finding 3 . Body Mass Index ( BMI ) ≥ 18.0 ≤ 32.0 kg/m2 4 . Subjects must use reliable form contraception ( barrier method spermicidal agent true abstinence ) must refrain sperm donation treatment 4week F/U period last treatment . 1 . Use investigational nonregistered product ( adjuvant , drug ) CV8102 within 4 week precede administration CV8102 , plan use agent trial period 2 . Subject receive licensed nonlicensed vaccine within 4 week prior administration CV8102 alone combination licensed rabies vaccine plan vaccination trial period 3 . Any treatment immunosuppressant immunemodifying drug within 6 month prior administration CV8102 alone combination licensed rabies vaccine . The use inhale nasal steroid , well topical steroid outside vaccination area , permit 4 . Any medically diagnose suspect immune deficient condition base medical history physical examination 5 . History autoimmune disease suspect autoimmune disease base medical history physical examination rule base examination 6 . Administration immunoglobulin ( Igs ) and/or blood product within 3 month precede administration CV8102 license rabies vaccine 7 . Acute disease time enrolment . Acute disease define presence acute condition include limited nonfebrile febrile common cold , urinary tract infection , inflammatory , allergic traumatic condition may interfere safety assessment investigational product 8 . Presence evidence significant acute chronic disease , particular heart disease include coronary artery disease chronic pulmonary disease ( e.g. , chronic obstructive pulmonary disease [ COPD ] ) ; uncontrolled medical psychiatric illness ( subject uncomplicated chronic diagnosis stable treat ≥ 3 month e.g. , mild hypertension wellcontrolled medication , may enrol provided condition therapy know associate immunocompromised state autoimmune disease ) 9 . Major congenital defect 10 . Known allergy component ( closely relate substance ) license rabies vaccine product 11 . Known type I allergy betalactam antibiotic 12 . Evidence current alcohol drug abuse 13 . History neurological disorder seizures 14 . Known seropositivity human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) ( except subject previously vaccinate HBV ) hepatitis C virus ( HCV ) 15 . Foreseeable noncompliance protocol judge Investigator 16 . History lifethreatening anaphylactic reaction 17 . Subjects impaired coagulation IM injection contraindicate . Additional exclusion criterion subject participate ( adjuvanted ) rabies vaccination part : 18 . Subject previously receive investigational licensed rabies vaccine 19 . Intending travel regions/countries rabies vaccination recommend high risk infection exist accord travel recommendation German Society Tropical Medicine International Health ( DTG ) trial F/U period 20 . Subject take chloroquine malaria treatment prophylaxis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>